The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Us On GoogleAdd as a preferred source on Google (WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the ...

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...

DUBLIN - July 17, 2017 - Medtronic plc (MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life ...

Medtronic Inc. (NYSE:MDT) got a thumbs up for its InterStim sacral nerve stimulation product’s clinical trials. The Minneapolis, Minn.-based device giant published new data on its InterStim device, ...

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...

Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...

Nat Clin Pract Urol. 2005;2(7):310-311. The InterStim® device has greatly increased the number of candidates for surgical therapy. This therapy involves an initial percutaneous nerve evaluation to ...

(RTTNews) - Medtronic plc. (MDT) said Monday that it has filed a pre-market approval or PMA supplement with the United States Food and Drug Administration or FDA for approval of its InterStim Micro ...